Molecular profile
Molecular profile
- Molecule class
- Peptide analogue
- Origin
- Synthetic analogue
- Primary target system
- GLP-1-Rezeptor
- Development stage
- Authorised active substance
Acyliertes GLP-1-Analogon mit verlängerter Halbwertszeit.
Mechanism and signalling
Mechanism and signalling
Its modification promotes albumin binding and prolongs exposure. Pharmacological activity is mediated through the GLP-1 receptor.
Scientific classification
Scientific classification
This profile maps Liraglutid to the research areas metabolism, endocrine. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.
Peptide hormones and analogues related to hypothalamic, pituitary and peripheral endocrine systems.
Evidence base
Approval and post-marketing data
Randomised trials, regulatory dossiers and long-term observations are available. This profile deliberately separates substance knowledge from treatment instructions.
Regulatory status
Authorised in the EU/multiple markets
The active substance is used in authorised medicines in multiple jurisdictions. Authorisations apply only to defined products, indications, quality standards and conditions of use.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries